Literature DB >> 10947060

Innate and adaptive immunity in Candida albicans infections and saprophytism.

L Romani1.   

Abstract

Underlying acquired immunity to the fungus Candida albicans is usually present in adult immunocompetent individuals and is presumed to prevent mucosal colonization progressing to symptomatic infection. Exploration of immunological events leading to Candida resistance or susceptibility has indicated the central role of the innate and adaptive immune systems, the relative contribution of which may vary depending on the site of the primary infection. Nevertheless, acquired resistance to infection results from the development of Th1 responses. Cytokines produced by Thl cells activate phagocytic cells to a candidacidal state. In contrast, cytokines produced by Th2 cells inhibit Th1 development and deactivate phagocytic effector cells. Because reciprocal influences have been recognized between innate and adaptive Th immunity, it appears that an integrated immune response determines the life-long commensalism of the fungus at the mucosal level, as well as the transition from mucosal saprophyte to pathogen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947060

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  34 in total

1.  Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Authors:  J Brieland; D Essig; C Jackson; D Frank; D Loebenberg; F Menzel; B Arnold; B DiDomenico; R Hare
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Lin Lin; Valentina Avanesian; Yue Fu; Peter Lipke; Henry Otoo; Tiffany Ho; John E Edwards
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

Review 3.  Immunology of dermatophytosis.

Authors:  Sandro Rogerio Almeida
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

4.  Bilateral chronic fungal dacryocystitis caused by Candida dubliniensis in a neutropenic patient.

Authors:  E Obi; A Roy; V Bates; C Sandy
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

5.  Cell surface changes in the Candida albicans mitochondrial mutant goa1Δ are associated with reduced recognition by innate immune cells.

Authors:  Xiaodong She; Lulu Zhang; Hui Chen; Richard Calderone; Dongmei Li
Journal:  Cell Microbiol       Date:  2013-03-28       Impact factor: 3.715

6.  The Pathophysiology and Treatment of Candida Sepsis.

Authors:  Brad Spellberg; John E. Edwards
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

7.  Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.

Authors:  Carla Bromuro; Antonella Torosantucci; Paola Chiani; Stefania Conti; Luciano Polonelli; Antonio Cassone
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Virulence attenuation of Candida albicans genetic variants isolated from a patient with a recurrent bloodstream infection.

Authors:  Paula Sampaio; Marlene Santos; Alexandra Correia; Fábio E Amaral; Julio Chavéz-Galarza; Sofia Costa-de-Oliveira; António G Castro; Jorge Pedrosa; Célia Pais
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

9.  Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis.

Authors:  Brad Spellberg; Douglas Johnston; Quynh Trang Phan; John E Edwards; Samuel W French; Ashraf S Ibrahim; Scott G Filler
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  Host-pathogen interaction and signaling molecule secretion are modified in the dpp3 knockout mutant of Candida lusitaniae.

Authors:  Ayman Sabra; Jean-Jacques Bessoule; Vessela Atanasova-Penichon; Thierry Noël; Karine Dementhon
Journal:  Infect Immun       Date:  2013-11-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.